Radius Health Inc Draws Bullish Options Activity Today

 Radius Health Inc Draws Bullish Options Activity Today

In today’s session Radius Health Inc (RDUS) registered an unusually high (253) contracts volume of call trades. Someone, most probably a professional was a very active buyer of the November, 2016 call, expecting serious RDUS increase. With 253 contracts traded and 4664 open interest for the Nov, 16 contract, it seems this is a quite bullish bet. The option with symbol: RDUS161118C00060000 closed last at: $0.5 or 47.4% down. About 291,553 shares traded hands. Radius Health Inc (NASDAQ:RDUS) has risen 23.56% since April 5, 2016 and is uptrending. It has outperformed by 21.60% the S&P500.

Radius Health Inc (NASDAQ:RDUS) Ratings Coverage

Out of 9 analysts covering Radius Health (NASDAQ:RDUS), 7 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 78% are positive. $90 is the highest target while $37 is the lowest. The $68.88 average target is 65.02% above today’s ($41.74) stock price. Radius Health has been the topic of 13 analyst reports since August 7, 2015 according to StockzIntelligence Inc. The stock of Radius Health Inc (NASDAQ:RDUS) has “Buy” rating given on Monday, May 23 by H.C. Wainwright. H.C. Wainwright maintained the shares of RDUS in a report on Wednesday, September 21 with “Buy” rating. JP Morgan initiated the shares of RDUS in a report on Friday, October 2 with “Overweight” rating. Canaccord Genuity maintained the shares of RDUS in a report on Thursday, September 24 with “Buy” rating. Cowen & Co reinitiated Radius Health Inc (NASDAQ:RDUS) on Friday, May 6 with “Outperform” rating. The rating was initiated by Goldman Sachs on Wednesday, March 30 with “Neutral”. Jefferies downgraded the shares of RDUS in a report on Wednesday, February 24 to “Hold” rating. The stock of Radius Health Inc (NASDAQ:RDUS) has “Buy” rating given on Friday, August 14 by Deutsche Bank.

According to Zacks Investment Research, “Radius Health Inc. is a science-driven biopharmaceutical company. It is focused on developing novel differentiated therapeutics for patients with osteoporosis as well as other serious endocrine-mediated diseases. The Company’s lead product candidate, abaloparatide (BA058), is in development, in both injection (Abaloparatide-SC) and transdermal (Abaloparatide-TD) methods of administration, for the prevention of fractures in post-menopausal women at risk of fracture from osteoporosis. Radius Health Inc. is based in Cambridge, Massachusetts.”

Insitutional Activity: The institutional sentiment increased to 1.32 in 2016 Q2. Its up 0.03, from 1.29 in 2016Q1. The ratio increased, as 20 funds sold all Radius Health Inc shares owned while 33 reduced positions. 22 funds bought stakes while 48 increased positions. They now own 42.68 million shares or 5.94% more from 40.29 million shares in 2016Q1.
The Cayman Islands-based Cqs Cayman Ltd Partnership has invested 0.65% in Radius Health Inc (NASDAQ:RDUS). Rhumbline Advisers has invested 0% of its portfolio in Radius Health Inc (NASDAQ:RDUS). Quantitative Systematic Strategies Ltd Limited Liability Company has 5,769 shares for 0.1% of their US portfolio. Artal Group Inc accumulated 100,000 shares or 0.08% of the stock. Millennium Management Ltd Liability Corp has invested 0.01% of its portfolio in Radius Health Inc (NASDAQ:RDUS). Cornerstone Advsrs holds 0.01% of its portfolio in Radius Health Inc (NASDAQ:RDUS) for 370 shares. Iguana Healthcare Management Ltd has 50,000 shares for 0.75% of their US portfolio. Blackrock Japan Limited last reported 0% of its portfolio in the stock. Fifth Third Fincl Bank accumulated 3,421 shares or 0% of the stock. Finemark Retail Bank & owns 264 shares or 0% of their US portfolio. The New York-based Tiaa Cref Invest Mgmt Limited Com has invested 0% in Radius Health Inc (NASDAQ:RDUS). Dimensional Fund Advisors Limited Partnership accumulated 0% or 11,514 shares. Mutual Of America Cap Management Ltd reported 36,283 shares or 0.03% of all its holdings. The New Jersey-based Architects has invested 0% in Radius Health Inc (NASDAQ:RDUS). State Street Corp holds 1.29 million shares or 0.01% of its portfolio.

Radius Health, Inc. is a biopharmaceutical firm focused on developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The company has a market cap of $1.67 billion. The Company’s product candidate, the investigational drug abaloparatide for subcutaneous injection, has completed Phase III development for use in the reduction of fracture risk in postmenopausal women with osteoporosis. It currently has negative earnings. The Company’s clinical pipeline also includes an investigational abaloparatide transdermal patch for use in osteoporosis and the investigational drug RAD1901 for use in hormone-driven and hormone-resistant breast cancer, and vasomotor symptoms in postmenopausal women.

RDUS Company Profile

Radius Health, Inc. is a biopharmaceutical firm focused on developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s product candidate, the investigational drug abaloparatide for subcutaneous injection, has completed Phase III development for use in the reduction of fracture risk in postmenopausal women with osteoporosis. The Company’s clinical pipeline also includes an investigational abaloparatide transdermal patch for use in osteoporosis and the investigational drug RAD1901 for use in hormone-driven and hormone-resistant breast cancer, and vasomotor symptoms in postmenopausal women. The Company’s preclinical pipeline includes RAD140, a non-steroidal, selective androgen receptor modulator (SARM) under investigation for use in cancer.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: , ,

Related posts

Leave a Comment